Biotricity, Inc.

For the third quarter of fiscal 2026, revenue increased 10.2% year over year to $4.0 million from $3.6 million. Gross profit was $3.3 million, up 17.6% from $2.8 million, and gross margin improved 516 basis points to 81.5% from 76.4%. Operating expenses were $2.8 million versus $2.93 million last year, down 4.2%. EBITDA was $280,000, operating income was $441,000, net loss attributable to common stockholders was $1.1 million versus $1.3 million last year, and loss per share was $0.042 versus $0.054. Management did not give formal next-quarter or full-year numeric guidance, but said revenue should continue to grow, the company expects to turn net income positive this year, and it is pursuing continued margin and expense improvement.

The CEO framed the quarter as another step in Biotricity’s move toward durable recurring growth, citing three straight quarters of positive net operating income and EBITDA. He emphasized demand for remote patient management, the expansion of its cardiac AI cloud platform, international regulatory progress, and growth in Biocore Pro and Bioheart. His tone was confident and upbeat, with repeated comments that the company is setting up for another growth year and expects to shift to profitability in 2026.

The CFO highlighted that revenue was $4.0 million, gross profit was $3.3 million, and gross margin improved to 81.5%, driven by a higher mix of recurring technology fees and lower cloud/monitoring costs. He said technology fees were 91.2% of quarterly revenue, operating expenses declined to $2.8 million, SG&A fell 8.2%, and R&D rose by $72,000. He also noted positive free cash flow for the last 6 consecutive quarters, positive EBITDA of $280,000, and operating profit of $441,000, saying these trends put the company on a path toward profitability.

There was no analyst Q&A on the call, as the operator stated there were no questions. Management therefore did not have to address follow-up concerns about the quarter, guidance, cash needs, or competitive risks. The closest substitute was management’s closing comment that it expects top-line growth and net income positivity this year.